Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
2
50%
Ph phase_4
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting1
Completed1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

not_yet_recruiting125%
completed125%
terminated125%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_3

A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

NCT07082855
terminatedphase_3

Minocycline in MS: Confirmation of Benefit

NCT04291456
unknownphase_4

Anti-inflammatories and Adolescent Schizophrenia

NCT04020588
completedphase_1

Bioequivalence Minocycline Bioequivalence

NCT01755611

Clinical Trials (4)

Showing 4 of 4 trials
NCT07082855Phase 3

A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

Not Yet Recruiting
NCT04291456Phase 3

Minocycline in MS: Confirmation of Benefit

Terminated
NCT04020588Phase 4

Anti-inflammatories and Adolescent Schizophrenia

Unknown
NCT01755611Phase 1

Bioequivalence Minocycline Bioequivalence

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4